-
11.26.2024 | CARB-X and CHAI partner to sharpen AMR response, tackle gonorrhea in low- and middle-income countries
CARB-X and the Clinton Health Access Initiative (CHAI) are partnering to evaluate the clinical needs and address market barriers for diagnostic, preventative, and therapeutic interventions targeting gonorrhea infections in low- and middle-income countries.
-
11.07.2024 | CARB-X applauds G20 Health Ministers’ commitments to control antimicrobial resistance
CARB-X is pleased to welcome the Rio de Janeiro Declaration of the G20 Health Ministers and the adjoined G20 Ministerial Declaration on Climate Change, Health and Equity and One Health, which were adopted at the G20 Health Ministerial Meeting in Rio de Janeiro on October 31.
-
10.31.2024 | CARB-X appoints Andy Soares White as Chief Financial Officer
CARB-X today announced the appointment of Andy Soares White to Chief Financial Officer (CFO). Soares White will oversee CARB-X’s financial operations, ensuring robust fiscal management and strategic allocation of resources.
-
10.18.2024 | Italy announces grant to CARB-X at G7 meeting
The Government of Italy has announced a commitment of US$21 million over the next three years to support the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). The announcement was made at the G7 Joint Finance and Health Ministers’ Meeting in Ancona on October 10, 2024.
-
09.27.2024 | CARB-X to support implementation of Political Declaration on AMR
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) welcomes the widespread support expressed by United Nations (UN) Member States to the Political Declaration on antimicrobial resistance (AMR) during the High-Level Meeting which took place yesterday (Thursday, September 26, 2024) at the 79th Session of the UN General Assembly (UNGA 79).
-
06.27.2024 | CARB-X funds Prompt Diagnostics to develop a diagnostic to detect drug-resistant gonorrhea
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding Prompt Diagnostics LLC US$1 million to further the development of a portable PCR platform with high multiplexing capabilities that, if successful, detect multiple pathogenic bacteria targets and their antibiotic susceptibility which will help to guide treatment at the point-of-care.
-
06.13.2024 | CARB-X funds Fuse Diagnostics to develop innovative, instrument-free diagnostic for chlamydia and drug-resistant gonorrhea
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1 million to Fuse Diagnostics to demonstrate proof-of-concept and feasibility ahead of the development of a rapid, instrument-free diagnostic for the detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). Fuse is a diagnostic company that uses new, multi-analytic chemistry to develop rapid, low-cost tests.
-
05.21.2024 | CARB-X funds University of Maryland to develop a vaccine to prevent neonatal sepsis
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding US$3.96 million to the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine to develop a maternal vaccine that prevents sepsis caused by Klebsiella pneumoniae in newborns and infants.
-
04.30.2024 | CARB-X 2023 Annual Report released today
The report highlights key takeaways from the strategic review of the portfolio, funding round results, CARB-X’s work in low- and middle-income countries (LMICs), and new CARB-X donors including the Government of Canada and the Novo Nordisk Foundation.
-
04.18.2024 | CARB-X funds Scout to develop a low-cost point-of-care diagnostic for gonorrhea
CARB-X is awarding Scout up to US$1M to demonstrate proof-of-concept and feasibility ahead of development of a new point-of-care test.
-
03.06.2024 | CARB-X launches new funding round to fill major R&D gaps in global pipeline
CARB-X seeks preventatives of invasive disease, diagnostics for neonatal sepsis and novel sample types for lower respiratory tract infections, and therapeutics for infections caused by gram-negative pathogens.
-
03.05.2024 | CARB-X funds 100th project targeting antibiotic resistance
CARB-X is awarding US$1.06 million to the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), our 100th project to address antibiotic resistance.
-
02.29.2024 | CARB-X funds GlyProVac to develop a novel vaccine to prevent sepsis in newborns
CARB-X is awarding GlyProVac US$467k to develop a maternal vaccine that targets Escherichia coli, a bacterial species that causes a large portion of neonatal sepsis infections.
-
02.27.2024 | CARB-X funds LimmaTech Biologics AG to develop a vaccine that prevents gonorrhea infections
CARB-X is awarding US$2.2 million to LimmaTech Biologics AG to advance the development of its novel vaccine candidate targeted to prevent Neisseria gonorrhoeae infections.
-
02.13.2024 | CARB-X funds the Myers Research Group to develop enhanced oral antibiotics to treat a range of serious drug-resistant bacterial infections
CARB-X is awarding US$1.2 million to the Andrew G Myers Research Group at the Harvard University Department of Chemistry and Chemical Biology to develop a series of enhanced oral antibiotics that directly target a range of antibiotic-resistant bacteria which cause serious lower respiratory tract and skin and soft tissue infections.
-
02.08.2024 | CARB-X funds Visby Medical to develop a portable rapid diagnostic for gonorrhea including antibiotic susceptibility
CARB-X is awarding up to US$1.8 million to biotechnology company, Visby Medical, to develop a portable rapid polymerase chain reaction (PCR) diagnostic to detect the presence of the pathogen that causes gonorrhea, Neisseria gonorrhoeae (NG), and its susceptibility to ciprofloxacin, a former frontline oral antibiotic that can no longer treat resistant NG.
-
01.18.2024 | CARB-X is funding Syntiron to develop a maternal vaccine to prevent neonatal sepsis
CARB-X is awarding Syntiron US$1.7 million to develop a maternal vaccine that targets Escherichia coli and Klebsiella pneumoniae, two bacterial species that cause a large portion of neonatal sepsis infections.
-
01.16.2024 | CARB-X is funding Intravacc to develop a vaccine that prevents gonorrhea infections
CARB-X is awarding US$633k to Intravacc to develop a vaccine that prevents Neisseria gonorrhoeae bacterial infections.
-
01.09.2024 | Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections
The Novo Nordisk Foundation is committing up to USD 25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections. The three-year grant will go to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the leading global non-profit public-private partnership in this space.
Toggle navigation